Costs of Treatment of Chronic Obstructive Pulmonary Disease
The aim of this study was to analyze direct costs of COPD therapy in relation with clinical course and stage of the disease. Sixty patients with moderate to severe COPD were included into the study. The average cost was taken from institutional data file and was also assessed from a social perspective. Results were presented as average costs per patient per year. Forty two percent of patients was classified as GOLD D category, while categories A, B, and C accounted for 8 %, 27 %, and 23 %, respectively. Approximately 65 % of patients had 2–3 degrees of dyspnea according to the Modified Medical Research Council Dyspnea Scale. About 60 % of patients underwent two or three exacerbations per year and those patients had one or two co-morbidities diagnosed. Treatment costs almost doubled with disease progression, mainly due to exacerbations. In patients in Group C and Group D with exacerbations the direct costs were several times higher than in group A or B and the difference increased with progression of the disease. In Groups A and B, the costs of treatment of stable disease or with exacerbation were comparable. We conclude that costs of treatment of COPD patients were highest in advanced disease and were strongly related to COPD exacerbations.
KeywordsCOPD Direct costs Exacerbations Medical costs Pharmacoeconomics
Ilona Zareba was supported by Leading National Research Center (KNOW), Bialystok, Poland.
Conflict of Interest
The authors declare no conflict of interest in relation to this article.
- Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178:332–338CrossRefPubMedGoogle Scholar
- Doherty DE, Belfer MH, Brunton SA, Fromer L, Morris CM, Snader TC (2006) Chronic obstructive pulmonary disease: consensus recommendations for early diagnosis and treatment. J Fam Pract 55(Suppl 1):51–58Google Scholar
- GOLD (2011) From the global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease. Available from: http://www.goldcopd.org. Accessed 15 Sept 2014
- Jahnz-Różyk K, Targowski T, From S (2011a) Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007-results of multicenter Polish study. Pol Merkur Lekarski 26:208–214Google Scholar
- Mannino DM (2003) Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 48(1185):1191Google Scholar
- Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J (2005) Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60:992–997CrossRefPubMedPubMedCentralGoogle Scholar
- WHO (2011) World Health Statistics 2011. Available from: http://www.who.int/entity/whosis/whostat/EN_WHS2011_Full.pdf. Accessed 10 Sept 2014